Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study

Outcomes from the Phase 3 MURANO trial support the efficacy of a two‑year regimen of venetoclax + rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL). To evaluate outcomes with the Belgian reimbursed VenR treatment strategy in routine clinical practice, we conducted a retrospective chart review of adults with R/R CLL prescribed VenR at nine clinical centers in Belgium. Data were collected from September 2019 until site‑specific ethical approval (October 2022–February 2023). 117 patients were included in the VenR-intended cohort, with records observed for a mean 19.2 (standard deviation, 10.5) months. At index, mean age was 71 years; 45% of patients had prior Bruton tyrosine kinase inhibitor (BTKi) exposure. Overall response rate was 90% among patients with an available response assessment. At 24 months, estimated overall survival (OS) was 80.8% (95% confidence interval [CI], 72.8%–89.6%), progression-free survival (PFS) was 77.5% (95% CI, 69.1%–87.0%). 82 patients (70​%) received ≥ 1 rituximab administration; 35 (​30%) did not, most commonly (71​%) due to COVID-19-related circumstances; 24-month OS and PFS were lower in patients not receiving rituximab (OS: 69.3% vs. 85.7%; PFS: 69.6% vs. 80.8%). BTKi-experienced patients had numerically lower 24-month OS (75.5% vs. 84.7%) and PFS (70.0% vs. 83.2%) than BTKi-naïve patients. Treatment discontinuations occurred in 39% of patients, and dose reductions in 29%. Mean daily venetoclax dose was 328.5 mg. Overall, real-world outcomes with the Belgian reimbursed VenR treatment strategy were broadly consistent with MURANO trial outcomes, despite substantial proportions of this sample having BTKi experience or never receiving rituximab.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-11-21
DOI
https://doi.org/10.1007/s00277-026-07356-8
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study

Joachim Morrens, Liesbeth F. E. Ghys, Barbara Gillon, Stef Meers et al.
Annals of Hematology
Chronic Lymphocytic Leukemia Research
article

Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study

Joachim Morrens, Liesbeth F. E. Ghys, Barbara Gillon, Stef Meers, Ann M. Janssens, Sylvia Snauwaert, Vincent Maertens, Laura Vandeweerd, Michel De Bevere, Laurens Poedts, Thomas Lettens
article en

Abstract

Outcomes from the Phase 3 MURANO trial support the efficacy of a two‑year regimen of venetoclax + rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL). To evaluate outcomes with the Belgian reimbursed VenR treatment strategy in routine clinical practice, we conducted a retrospective chart review of adults with R/R CLL prescribed VenR at nine clinical centers in Belgium. Data were collected from September 2019 until site‑specific ethical approval (October 2022–February 2023). 117 patients were included in the VenR-intended cohort, with records observed for a mean 19.2 (standard deviation, 10.5) months. At index, mean age was 71 years; 45% of patients had prior Bruton tyrosine kinase inhibitor (BTKi) exposure. Overall response rate was 90% among patients with an available response assessment. At 24 months, estimated overall survival (OS) was 80.8% (95% confidence interval [CI], 72.8%–89.6%), progression-free survival (PFS) was 77.5% (95% CI, 69.1%–87.0%). 82 patients (70​%) received ≥ 1 rituximab administration; 35 (​30%) did not, most commonly (71​%) due to COVID-19-related circumstances; 24-month OS and PFS were lower in patients not receiving rituximab (OS: 69.3% vs. 85.7%; PFS: 69.6% vs. 80.8%). BTKi-experienced patients had numerically lower 24-month OS (75.5% vs. 84.7%) and PFS (70.0% vs. 83.2%) than BTKi-naïve patients. Treatment discontinuations occurred in 39% of patients, and dose reductions in 29%. Mean daily venetoclax dose was 328.5 mg. Overall, real-world outcomes with the Belgian reimbursed VenR treatment strategy were broadly consistent with MURANO trial outcomes, despite substantial proportions of this sample having BTKi experience or never receiving rituximab.

Annals of Hematology
Pierre Fabre (Germany) (DE), Universitair Ziekenhuis Leuven (BE), AZ Klina (BE), AZ Sint-Jan (BE), Imelda Hospital (BE), Abbott (Belgium) (BE)
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon